Hospital price transparency and 340B reform should be pillars of the Make America Healthy Again agenda. Both seek to expose hidden financial arrangements and bring greater accountability to how our healthcare dollars are being spent.
The Trump administration is making hospital price transparency a centerpiece of its Make America Healthy Again agenda — and it has a chance to go even further toward achieving this goal.
Earlier this month, federal regulators warned more than 500 hospitals that they could be violating federal requirements to disclose their prices. The message from the administration was simple. Patients deserve to know what healthcare costs.
Yet transparency shouldn’t stop at hospital prices. If the administration is serious about exposing hidden financial arrangements in healthcare, it should turn its attention to the federal 340B drug-pricing program, which has allowed hospitals to retain billions of dollars in drug discounts intended to help vulnerable patients.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Trump’s Push for Healthcare Transparency, Starting With Hospital Prices, Can Go Even Further
Sally C. Pipes
Hospital price transparency and 340B reform should be pillars of the Make America Healthy Again agenda. Both seek to expose hidden financial arrangements and bring greater accountability to how our healthcare dollars are being spent.
The Trump administration is making hospital price transparency a centerpiece of its Make America Healthy Again agenda — and it has a chance to go even further toward achieving this goal.
Earlier this month, federal regulators warned more than 500 hospitals that they could be violating federal requirements to disclose their prices. The message from the administration was simple. Patients deserve to know what healthcare costs.
Yet transparency shouldn’t stop at hospital prices. If the administration is serious about exposing hidden financial arrangements in healthcare, it should turn its attention to the federal 340B drug-pricing program, which has allowed hospitals to retain billions of dollars in drug discounts intended to help vulnerable patients.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.